NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis

Abstract Substantial researches indicated that long non-coding RNAs (lncRNAs) exerted profound effects on chemo-resistance in cancer treatment. Nonetheless, the role of NORAD in non-small-cell lung cancer (NSCLC) remains unclear. In the present study, we chose NSCLC cell lines H446 and A549 to explore the function of non-coding RNA activated damage (NORAD) in response to cisplatin (DDP) resistance of NSCLC. Experimental data manifested that NORAD was up-regulated in DDP-resistant NSCLC tissues and cells. NSCLC patients with high NORAD expression suffered a poor prognosis. NORAD knockdown resensitized H446/DDP and A549/DDP to DDP. Besides, NORAD acted as a molecular sponge of miR-129-1-3p. MiR-129-1-3p showed a low level of expression in DDP-resistant NSCLC tissues. Moreover, miR-129-1-3p overexpression impaired DDP resistance in H446/DDP and A549/DDP cells. SOX4 was the downstream target of miR-129-1-3p. Especially, SOX4 overexpression offset the effects of NORAD silence on H446/DDP and A549/DDP cells resistance to DDP. NORAD knockdown resensitized H446/DDP and A549/DDP to DDP in NSCLC via targeting miR-129-1-3p/SOX4 axis, offering a brand-new target for NSCLC chemo-resistance.

Download Full-text

Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer

Cancers ◽

10.3390/cancers10080245 ◽

2018 ◽

Vol 10 (8) ◽

pp. 245 ◽

Cited By ~ 14

Author(s):

Yosuke Miura ◽

Noriaki Sunaga

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Checkpoint Inhibitors ◽

Genetic Alterations ◽

Small Cell ◽

Small Cell Lung ◽

Future Direction ◽

Nsclc Patients

The clinical application of immune checkpoint inhibitors (ICIs) has led to dramatic changes in the treatment strategy for patients with advanced non-small cell lung cancer (NSCLC). Despite the observation of improved overall survival in NSCLC patients treated with ICIs, their efficacy varies greatly among different immune and molecular profiles in tumors. Particularly, the clinical significance of ICIs for oncogene-driven NSCLC has been controversial. In this review, we provide recent clinical and preclinical data focused on the relationship between oncogenic drivers and immunological characteristics and discuss the future direction of immunotherapy in NSCLC patients harboring such genetic alterations

Download Full-text

The Predictive Role of the 53BP1 Pathway in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (P) Treated with First-Line Platinum-Based Chemotherapy

Annals of Oncology ◽

10.1016/s0923-7534(20)34205-8 ◽

2012 ◽

Vol 23 ◽

pp. ix533

Author(s):

L. Bonanno ◽

C. Costa ◽

M. Majem ◽

A. Gimenez-Capitan ◽

I. Rodriguez ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Platinum Based Chemotherapy ◽

Predictive Role ◽

Nsclc Patients

Download Full-text

Role of long non-coding RNA in drug resistance in non-small cell lung cancer

Thoracic Cancer ◽

10.1111/1759-7714.12652 ◽

2018 ◽

Vol 9 (7) ◽

pp. 761-768 ◽

Cited By ~ 21

Author(s):

Leirong Wang ◽

Leina Ma ◽

Fei Xu ◽

Wenxin Zhai ◽

Shenghua Dong ◽

...

Keyword(s):

Lung Cancer ◽

Drug Resistance ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Non Coding Rna ◽

Long Non Coding Rna

Download Full-text

REV3L Gene Variants rs1002481, rs462779, and rs465646 Lead to Increased Susceptibility Towards Non-Small Cell Lung Cancer in the Population of Jammu and Kashmir.

10.21203/rs.3.rs-42137/v1 ◽

2020 ◽

Author(s):

Rajeshwar Singh Jamwal ◽

Nikita Mahajan ◽

Gh. Rasool Bhat ◽

Amrita Bhat ◽

Bhanu Sharma ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Strong Association ◽

Gene Mutations ◽

Small Cell ◽

Small Cell Lung ◽

Jammu And Kashmir ◽

Nsclc Patients

Abstract Background: Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer accounting for 80–85% of all lung cancer cases. Various genetic studies have tried to reveal the association of REV3L (Protein reversion less 3-like) gene mutations with cancer, including lung cancer but no such study has been carried out in the population of Jammu and Kashmir (J&K).Methods: The selected REV3L variants were genotyped using the TaqMan allele discrimination assay in 550 subjects (203 NSCLC patients and 347 healthy controls). The association of variants was evaluated by logistic regression.Results: Out of the four REV3L variants genotyped, we found rs1002481, rs462779, and rs465646 significantly associated with NSCLC risk with an Odds Ratio (OR) of 3.5 (1.98–6.3 at 95% CI ), p value = 0.00002; OR = 4.4 (1.8–10.4 at 95% CI ), p value = 0.00075; and OR = 2.4 (1.47–4.008 at 95% CI ), p value = 0.00053, respectively.Conclusion: Our data suggest a strong association of variants rs1002481, rs462779, rs465646 with NSCLC. This association is indicative of a potential role of mutations in the REV3L gene as risk factor for the development of NSCLC in the studied population. Although a first report from any Indian population, these variants have been previously reported to be associated with lung and colorectal cancers in different world populations. These data along with our data supports the notation that these variants can be used as potential prognostic biomarker.

Download Full-text

The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer

Journal of Clinical Medicine ◽

10.3390/jcm9061918 ◽

2020 ◽

Vol 9 (6) ◽

pp. 1918 ◽

Cited By ~ 1

Author(s):

Ramon Andrade De Mello ◽

Nathália Moisés Neves ◽

Giovanna Araújo Amaral ◽

Estela Gudin Lippo ◽

Pedro Castelo-Branco ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Adverse Reactions ◽

Small Cell ◽

Small Cell Lung ◽

Nsclc Patients ◽

Phase Ii And Iii ◽

Mesenchymal Epithelial Transition

Introduction: Non-small cell lung cancer (NSCLC) is the second most common cancer globally. The mesenchymal-epithelial transition (MET) proto-oncogene can be targeted in NSCLC patients. Methods: We performed a literature search on PubMed in December 2019 for studies on MET inhibitors and NSCLC. Phase II and III clinical trials published in English between 2014 and 2019 were selected. Results: Data on MET inhibitors (tivantinib, cabozantinib, and crizotinib) and anti-MET antibodies (emibetuzumab and onartuzumab) are reported in the text. Conclusion: Emibetuzumab could be used for NSCLC cases with high MET expression. Further, studies on onartuzumab failed to prove its efficacy, while the results of tivantinib trials were clinically but not statistically significant. Additionally, cabozantinib was effective, but adverse reactions were common, and crizotinib was generally well-tolerated.

Download Full-text